This comparison is arguably the most important in metabolic medicine heading into 2026, as it pits the two pharmaceutical giants against each other in the competition for the best-in-class obesity treatment
131 , 132 Other molecules of levodopa are degraded by the endothelial enzyme monoamine oxidase B in the periphery, 133 although drugs such as carbidopa are now available to inhibit this enzyme
Heres the thing, too much ammonia is bad for the human body, especially the brain
September 1, 2025 Teva Pharmaceuticals achieved a landmark milestone when the US Food and Drug Administration (FDA) approved a first-of-its-kind launch of a generic glucagon-like peptide-1 (GLP-1)
Acute intracerebral treatment with amyloid-beta (142) alters the profile of neuronal oscillations that accompany LTP induction and results in impaired LTP in freely behaving rats
The Golden Era of Incretin Therapy: A Visual Summary As an Endocrinologist, keeping pace with the rapid evolution of GLP-1 Receptor Agonists (and the new twincretins) is both a challenge and a privilege